Responsibilities of the team, page-102

Hi again dear Titans ,
I already did, say my thoughts on where I see Race is going .

I hope you have a nice weekend .

Good things to ponder , if we are holding RAC , and in our investing ongoing here .
Imo - as have said on multiple occasions in RAC threads .
No 1 the company is working to commercialise Bisantrene- when achieved this would be worth , starting values , north of $300 million USD .
( for refractory AML treatment alone, if shown to be the answer with ensuring no residual measurable disease - MRD -ve aim - then would be I think higher. * my idea - as starting price for All on AML alone )

The real value will be if proven and approved for one treatment- extended out treatment prescription can then be indicated and Bisantrene administered for if proof already exists . Safety is already well and truly proven

Bisantrene is already phase 3 and beyond as the company explained since it already has been fully approved and in use in the past, in France, for AML .
——————————————————————-
I hope - Bisantrene will soon be back in cancer clinics being given to direly ill breast and ovarian cancer patients.
Race already knows the optimal dosages to administer now in 2020 .
And there was past clinical responses, in breast and ovarian cancer patients- after being given only a much lower , less than optimal administration ( peripheral rather than central line drug administration) using Bisantrene.
**Right dose and pathway— Will be very exciting !
Just have to have it at last available and administered instead of existing nastier chemotherapy treatments.

Bisantrene as favoured chemotherapy drug , 5/2 days or 7/2 , with perhaps followup washout several weeks later to knockout the cancer cells - whether for MRD or primarily I hope with time - instead of some existing archaic and detrimental chemotherapy drugs which have been in use since the 1960s/70s ! , hugely used and given routinely ( Doxyrubicin)

I look forward to seeing , I hope , clearly time is needed to fully approve and undertake the trials - but see it even REPLACE DOXYRUBICIN, I hope !

Bisantrene- especially also of course in refractory AML ,we hope to again see it available.
Bisantrene can be given to very sick children and elderly people suffering terminal cancers , leukaemias & blood cancer patients.
Their treatment options are otherwise now very limited , with arguable - futility and deleterious effects to undergo treatments available .
Then— with low percentages of efficacy towards a CR ( remission measurements ) and even worse, morbid side effects and short life expectancies of less than another year of life with most treatments they can
undergo..
IF— indeed patients and their families decide it is worth it .

Bisantrene is a good chemotherapeutic drug without the terrible heart damage and permanent harm, and or significant side effects which children and elderly or medically compromised patients cannot even tolerate .
Lets prove this again . Back in the 1990s even the diagnostics to measure cardiac , heart muscle damage didn’t exist so well as now .
Which made them not regard , the severity of agents , ie. Doxyrubicin, which was already approved , compared to what all the Bisantrene trials pointed to .
Bisantrene —- no cardiac harm , or the ongoing similar damage as occurs with existing standard of care chemotherapy initially given for very sick cancer patients .
Perhaps these days - it would have been Doxyrubicin, knocked out from being fully approved for use , although it is excellent at killing cancer cells .... it can also , often contribute to killing the patient.
**The 1980s - we called the graveyard era . Everything was - Hit is as hard as you can , with as much as you have , knockout treatment for survival.
(Study was the same - more and more information coming to light - throw it All at undergraduate students and make them learn the lot , by rote . Without lengthening the (University) Courses .

If they had had better diagnostics , including measuring True cardiac harm , and more specialist doctors and parameters of care — imo they would have re- looked at the other related class of agents - which is Bisantrene.
** The US and the expense to take a drug through to approvals was prohibitive and large pharmaceutical companies determined what could progress . They also had main interest in protecting the values and marketability of their own IP pipeline and existing drugs to market . There was just no money in Oncology .

If had been not lost - hopefully, Bisantrene could have been in use , as an approved agent in more countries , and since way back then in the 1990s .
Especially if heart damage had been a significant parameter .

It was just a very unfortunate thing which occurred - made far more tragic knowing that many, many people could have survived and be alive today if it had been able to run through the full course to approvals in the US .
Aggressive takeover of the partner pharmaceutical drug production company, who were in debt -
Bisantrene didn’t even get lookin . Wyeth were not yet Wyeth .. and Pfizer had major corporate ambitions . Entire research units were simply abandoned . ( Wyeth were a non- oncology pharmacy company )
——————————————————————-
Bisantrene is very worthy .
I think we see it brought into trials , in the pathways determined - and hope to see it soon helping to save cancer patients lives.
And be brought to market , globally . ( with obviously a much larger, Pharmaceutical company )


All the best